Breaking News Instant updates and real-time market news.

CF

CF Industries

$41.77

0.395 (0.95%)

06:26
12/19/18
12/19
06:26
12/19/18
06:26

Stephens upgrades CF Industries to Overweight, sees improved risk/reward

Stephens analyst Mark Connelly upgraded CF Industries to Overweight from Equal Weight and raised his price target for the shares to $60 from $55. The analyst expects "solid" nitrogen demand to keep CF volumes high, even if the cost curve is flatter. The stock at current levels is reflecting a flatter curve than is likely, which brings an improved risk/reward profile, Connelly tells investors in a research note. Further, he estimates CF's leverage will drop to a "comfortable" 2.4 times by year end. The company's free cash potential over the next two years can average greater than $5 per share, contends the analyst.

CF CF Industries
$41.77

0.395 (0.95%)

12/19/18
SPHN
12/19/18
UPGRADE
SPHN
Overweight
CF Industries upgraded to Overweight from Equal Weight at Stephens
11/02/18
SBSH
11/02/18
UPGRADE
Target $60
SBSH
Buy
CF Industries upgraded to Buy with $60 price target at Citi
Citi analyst P.J. Juvekar upgraded CF Industries to Buy from Neutral and raised his price target for the shares to $60 from $56. With the over 10% pullback in shares over the past few weeks, and "all signs pointing to a strong spring" for U.S. urea fundamentals, CF Industries is attractive, Juvekar tells investors in a research note. CF is calling for U.S. Gulf urea price range of $260-$310/ton in 2019, which the analyst views as conservative.
11/02/18
SBSH
11/02/18
UPGRADE
Target $60
SBSH
Buy
CF Industries upgraded to Buy from Neutral at Citi
Citi analyst P.J. Juvekar upgraded CF Industries to Buy and raised his price target for the shares to $60 from $56.
10/31/18
BOFA
10/31/18
UPGRADE
Target $55
BOFA
Buy
CF Industries upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill analyst Steve Byrne double upgraded CF Industries to Buy from Underperform and increased its price target to $55 from $44. Byrne said there has been a rally in EU natural gas prices forming a steeper cost curve, and Chinese exports have been low, keeping global supplies tight. The analyst believes recent strength in nitrogen pricing is sustainable based on expectations EU gas prices above $9/MMBtu through 2019, below normal US retail inventories, and below normal year-to-date US nitrogen imports.

TODAY'S FREE FLY STORIES

CTLT

Catalent

$48.83

-0.39 (-0.79%)

07:22
10/17/19
10/17
07:22
10/17/19
07:22
Initiation
Catalent initiated  »

Catalent resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 05

    Nov

CDEV

Centennial Resource Development

$3.42

0.09 (2.70%)

07:22
10/17/19
10/17
07:22
10/17/19
07:22
Hot Stocks
Centennial Resource Development appoints Steven Shapiro to board of directors »

Centennial Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

CAKE

Cheesecake Factory

$38.41

0.06 (0.16%)

07:21
10/17/19
10/17
07:21
10/17/19
07:21
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 04

    Nov

  • 12

    Nov

NFLX

Netflix

$286.83

2.59 (0.91%)

07:20
10/17/19
10/17
07:20
10/17/19
07:20
Recommendations
Netflix analyst commentary  »

Netflix guidance adds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AKG

Asanko Gold

$0.90

-0.0083 (-0.91%)

, GFI

Gold Fields

$5.52

0.15 (2.79%)

07:19
10/17/19
10/17
07:19
10/17/19
07:19
Hot Stocks
Asanko Gold reports Q3 AGM gold production of 62,440 ounces »

Asanko Gold (AKG)…

AKG

Asanko Gold

$0.90

-0.0083 (-0.91%)

GFI

Gold Fields

$5.52

0.15 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$286.83

2.59 (0.91%)

07:17
10/17/19
10/17
07:17
10/17/19
07:17
Recommendations
Netflix analyst commentary  »

Stifel keeps Buy rating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

OLN

Olin

$18.25

-0.015 (-0.08%)

, WLK

Westlake Chemical

$62.28

-0.24 (-0.38%)

07:17
10/17/19
10/17
07:17
10/17/19
07:17
Downgrade
Olin, Westlake Chemical rating change  »

JPMorgan downgrades Olin…

OLN

Olin

$18.25

-0.015 (-0.08%)

WLK

Westlake Chemical

$62.28

-0.24 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 05

    Nov

NURO

NeuroMetrix

$0.32

-0.0249 (-7.21%)

07:15
10/17/19
10/17
07:15
10/17/19
07:15
Earnings
NeuroMetrix reports Q3 revenue $2.1M, one estimate $3.93M »

"A new commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 12

    Nov

NFLX

Netflix

$286.83

2.59 (0.91%)

07:13
10/17/19
10/17
07:13
10/17/19
07:13
Recommendations
Netflix analyst commentary  »

Netflix's Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

CMA

Comerica

$65.50

-1.505 (-2.25%)

07:13
10/17/19
10/17
07:13
10/17/19
07:13
Downgrade
Comerica rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBI

Texas Capital

$54.33

-0.15 (-0.28%)

07:12
10/17/19
10/17
07:12
10/17/19
07:12
Recommendations
Texas Capital analyst commentary  »

Texas Capital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:11
10/17/19
10/17
07:11
10/17/19
07:11
Hot Stocks
Philip Morris backs FY19 currency-neutral net revenue growth of at least 6% »

Lowers FY19 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

GOLD

Barrick Gold

$16.95

0.3 (1.80%)

07:11
10/17/19
10/17
07:11
10/17/19
07:11
Hot Stocks
Barrick Gold sees FY production towards upper end of 5.1M-5.6M ounce guidance »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PFE

Pfizer

$36.34

-0.17 (-0.47%)

07:10
10/17/19
10/17
07:10
10/17/19
07:10
Initiation
Pfizer initiated  »

Pfizer reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

MAIN

Main Street

$42.08

0.155 (0.37%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Main Street declares semi-annual supplemental cash dividend of 24c in December »

Main Street declared its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Pool Corp. raises FY19 EPS view $6.20-$6.40 from $6.09-$6.34 

Consensus $6.22.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

PM

Philip Morris

$79.12

0.8 (1.02%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Hot Stocks
Philip Morris revises FY19 shipment volume assumption to "down 1% - down 1.5" »

Prior guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AZN

AstraZeneca

$43.80

-0.41 (-0.93%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Hot Stocks
AstraZeneca says trastuzumab deruxtecan granted FDA Priority Review »

AstraZeneca and Daiichi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Earnings
Pool Corp. reports Q3 EPS ex-items $1.84, consensus $1.78 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

TXMD

TherapeuticsMD

$3.70

-0.22 (-5.61%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Initiation
TherapeuticsMD initiated  »

TherapeuticsMD initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Earnings
Philip Morris lowers FY19 EPS view to 'at least $4.73' from 'at least $4.94' »

Consensus $5.21. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NFLX

Netflix

$286.83

2.59 (0.91%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Recommendations
Netflix analyst commentary  »

KeyBanc lowers estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

NBRV

Nabriva Therapeutics

$2.01

0.08 (4.15%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Conference/Events
Nabriva Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

BBIO

BridgeBio

$17.92

-0.6 (-3.24%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
BridgeBio reports preclinical data on infigratinib in treating achondroplasia »

BridgeBio Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB

$0.00

(0.00%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
UCB says bimekizumab Phase 3 psoriasis study meets all endpoints »

UCB announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.